XML 79 R56.htm IDEA: XBRL DOCUMENT v3.22.2
SHARE-BASED COMPENSATION (Tables)
12 Months Ended
Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of share options activity

The following table sets forth the share options activities for the year ended December 31, 2019, the three months ended March 31,2020, the fiscal years ended March 31, 2021 and 2022:

 

 

 

Number of shares

 

 

Weighted-average exercise price

 

 

Weighted average remaining contractual term

 

 

Aggregate
intrinsic
value

 

 

Weighted average fair value of options

 

 

 

 

 

 

US$

 

 

YEARS

 

 

US$’000

 

 

US$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2018

 

 

55,195,000

 

 

 

1.85

 

 

 

7.74

 

 

 

27,773.18

 

 

 

2.03

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

4,247,500

 

 

 

1.36

 

 

 

 

 

 

 

 

 

0.02

 

Forfeited

 

 

(11,454,468

)

 

 

2.36

 

 

 

 

 

 

 

 

 

2.65

 

Exercised

 

 

(6,772,504

)

 

 

0.03

 

 

 

 

 

 

 

 

 

0.54

 

Modified

 

 

(5,873,482

)

 

 

2.82

 

 

 

 

 

 

 

 

 

2.95

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding as of December 31, 2019

 

 

35,342,046

 

 

 

1.81

 

 

 

8.33

 

 

 

31,391.17

 

 

 

1.72

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

2,175,300

 

 

 

0.03

 

 

 

 

 

 

 

 

 

0.49

 

Forfeited

 

 

(5,186,508

)

 

 

1.14

 

 

 

 

 

 

 

 

 

2.09

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding as of March 31, 2020

 

 

32,330,838

 

 

 

1.79

 

 

 

6.81

 

 

 

25,530.99

 

 

 

1.58

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

6,700,665

 

 

 

0.01

 

 

 

 

 

 

 

 

 

0.39

 

Forfeited

 

 

(9,794,727

)

 

 

1.17

 

 

 

 

 

 

 

 

 

2.13

 

Exercised

 

 

(3,482,103

)

 

 

0.08

 

 

 

 

 

 

 

 

 

0.59

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding as of March 31, 2021

 

 

25,754,673

 

 

 

1.79

 

 

 

6.18

 

 

 

3,974.57

 

 

 

1.20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

1,266,357

 

 

 

0.01

 

 

 

 

 

 

 

 

 

0.57

 

Forfeited

 

 

(1,681,323

)

 

 

1.34

 

 

 

 

 

 

 

 

 

2.58

 

Exercised

 

 

(6,826,300

)

 

 

0.36

 

 

 

 

 

 

 

 

 

0.67

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding as of March 31, 2022

 

 

18,513,407

 

 

 

0.75

 

 

 

6.01

 

 

 

2,405.17

 

 

 

1.23

 

Vested and expected to vest as of
   March 31, 2022

 

 

18,513,407

 

 

 

0.75

 

 

 

6.01

 

 

 

2,405.17

 

 

 

1.23

 

Exercisable as of March 31, 2022

 

 

17,375,277

 

 

 

0.56

 

 

 

5.93

 

 

 

2,282.78

 

 

 

1.26

 

Schedule of options granted to Grantees were measured at fair value on the dates of grant

Options granted to Grantees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions:

 

 

 

For the year ended December 31,

 

 

For the three months ended March 31,

 

 

For the fiscal year ended March 31,

 

 

For the fiscal year ended March 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expected volatility

 

44%~45%

 

 

46%~49%

 

 

48%~61%

 

 

34%~68%

 

Risk-free interest rate (per annum)

 

1.6%~1.9%

 

 

0.3%~0.7%

 

 

0%~1.4%

 

 

0%~2.4%

 

Exercise multiple

 

2.8/2.2

 

 

2.8/2.2

 

 

2.8/2.2

 

 

2.8/2.2

 

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

 

 

0

%

Contractual term (in years)

 

 

10

 

 

 

10

 

 

 

10

 

 

 

10

 

Summary of restricted shares activity

The following table sets forth the restricted shares activity for the year ended December 31, 2019, the three months ended March 31, 2020, the fiscal years ended March 31, 2021 and 2022:

 

 

 

Number of
shares

 

 

Weighted average grant date fair value

 

 

 

 

 

 

US$

 

 

 

 

 

 

 

 

Unvested as of December 31, 2018

 

 

133,334

 

 

 

2.26

 

 

 

 

 

 

 

 

Granted

 

 

151,655

 

 

 

1.41

 

Vested

 

 

(184,988

)

 

 

0.75

 

Forfeited

 

 

(66,667

)

 

 

2.26

 

 

 

 

 

 

 

 

Unvested as of December 31, 2019

 

 

33,334

 

 

 

2.26

 

 

 

 

 

 

 

 

Granted

 

 

50,066

 

 

 

0.51

 

Vested

 

 

(50,066

)

 

 

0.51

 

 

 

 

 

 

 

 

Unvested as of March 31, 2020

 

 

33,334

 

 

 

2.26

 

 

 

 

 

 

 

 

Granted

 

 

275,850

 

 

 

0.45

 

Vested

 

 

(309,184

)

 

 

0.65

 

 

 

 

 

 

 

 

Unvested as of March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

606,570

 

 

 

0.42

 

Vested

 

 

(606,570

)

 

 

0.42

 

 

 

 

 

 

 

 

Unvested as of March 31, 2022

 

 

 

 

 

 

Summary of Share-Based Compensation Expenses by Function

The following table sets forth the amounts of share-based compensation expenses continuing operations included in each of the relevant financial statement line items:

 

 

 

For the year ended December 31,

 

 

For the three months ended March 31,

 

 

For the fiscal year ended March 31,

 

 

For the fiscal year ended March 31,

 

 

 

2019

 

 

2020

 

 

2021

 

 

2022

 

 

 

RMB

 

 

RMB

 

 

RMB

 

 

RMB

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

 

 

 

 

 

 

2,149

 

 

 

 

Sales and marketing expenses

 

 

 

 

 

 

 

 

5,036

 

 

 

 

Research and development expenses

 

 

194

 

 

 

(2,158

)

 

 

(2,216

)

 

 

 

General and administrative expenses

 

 

84,265

 

 

 

(29,925

)

 

 

(24,091

)

 

 

26,534

 

Total

 

 

84,459

 

 

 

(32,083

)

 

 

(19,122

)

 

 

26,534

 

Performance Awards  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of options granted to Grantees were measured at fair value on the dates of grant The fair value of Performance Awards with market conditions granted was determined using a Monte Carlo model with the following assumptions:

 

 

 

For the fiscal year ended March 31,

 

 

 

2022

 

 

 

 

 

Risk-free interest rate

 

 

1.12

%

Expected volatility

 

 

46

%

Expected dividend yield

 

 

0

%